Acute coronary syndrome (ACS) encompasses conditions stemming from decreased blood flow to the heart, such as unstable angina, NSTEMI, and STEMI, necessitating swift medical intervention due to the risk of serious complications such as heart attacks. Within the ACS market, a prominent trend is the shift towards precision medicine, leveraging genetic insights and biomarkers to tailor treatments to individual patients. This approach, coupled with the adoption of innovative antithrombotic agents and non-invasive diagnostics, is enhancing treatment effectiveness and patient outcomes. Increased R&D investment is driving the development of next-gen therapies and diagnostics, fostering a patient-centered care paradigm focused on addressing unmet clinical needs and advancing ACS management.
Global Acute Coronary Syndrome Market is projected to reach USD 14,810.38 million by 2029, with a CAGR of 5.2% during the forecast period of 2022-2029.
To know more, visit https://www.databridgemarketresearch.com/zh/reports/global-acute-coronary-syndrome-market
Below are the Top Acute Coronary Syndrome Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Novartis AG
|
Novartis AG is a global pharmaceutical company known for its cardiovascular portfolio, including drugs such as Entresto for heart failure. In the acute coronary syndrome (ACS) market, Novartis focuses on innovative therapies targeting underlying disease mechanisms, aiming to improve patient outcomes and reduce the risk of recurrent events.
|
|
Americas, Europe, Asia-Pacific, and Middle East and Africa
|
In October 2021, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid rehospitalization in a country where heart disease is on the rise.
|
|
2.
|
AstraZeneca
|
AstraZeneca is a leading biopharmaceutical company with a strong presence in cardiovascular medicine, offering medications such as Brilinta for ACS management. AstraZeneca emphasizes research and development to advance treatments for ACS, striving to address unmet medical needs and enhance patient care through innovative therapies and diagnostic solutions.
|
|
North America, Europe, Asia-Pacific, and Africa
|
In December 2020, Astra Zeneca announced that the company had acquired Alexion, a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. This helps in accelerating the company’s strategic and financial developments that deliver life-changing medicines for patients.
|
|
3.
|
Amgen Inc.
|
Amgen Inc. is a biotechnology company renowned for its cardiovascular medications, including Repatha, for lowering cholesterol. In the ACS market, Amgen prioritizes precision medicine approaches, leveraging genetic insights to develop targeted therapies tailored to individual patients, aiming to improve treatment efficacy and outcomes.
|
|
North America, South America, Asia-Pacific, Europe, and Middle East and Africa
|
In February 2022, Amgen and Plexium, Inc. announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules. Collaborating with Plexium and leveraging their innovative technology to identify molecular glue degraders can help tackle some of the most challenging protein targets to address serious diseases.
|
|
4.
|
Sanofi
|
Sanofi is a multinational pharmaceutical company with a diverse cardiovascular product portfolio featuring medications such as Plavix for preventing blood clots. In the ACS market, Sanofi emphasizes the development of novel antithrombotic agents and non-invasive diagnostic tools, striving to enhance treatment effectiveness and patient safety through innovative solutions.
|
|
North America, Europe, Asia-Pacific
|
In November 2021, Sanofi announced that the company had completed the acquisition of Kadmon, a biopharmaceutical company delivering transformative therapies for unmet medical needs. This results in the expansion of the General Medicines portfolio, leading to an increase in the demand for its product in the market.
|
|
5.
|
Baxter
|
Baxter is a global healthcare company known for its expertise in medical devices and pharmaceuticals, offering products such as heparin for anticoagulation therapy. In the ACS market, Baxter focuses on providing essential therapies and supportive care solutions to improve patient outcomes and optimize the management of acute coronary events.
|
|
Europe, Asia-Pacific, South America, North America, and Middle East and Africa
|
In December 2021, Baxter International Inc. announced it had completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion. The Baxter-Hillrom combination unlocks the next phase of company transformation, presenting a new wave of potential to drive a more significant impact for patients, clinicians, employees, shareholders, and other communities that the company serves worldwide. The combination unites two leading medtech organizations in a shared vision for transforming healthcare and advancing patient care worldwide.
|
Conclusion
In the acute coronary syndrome (ACS) market, prominent pharmaceutical and biotechnology companies such as Novartis AG, AstraZeneca, Amgen Inc., Sanofi, and Baxter play pivotal roles in advancing patient care. Through their diverse portfolios and focus on innovation, these companies contribute significantly to addressing the complex challenges associated with ACS management. Their commitment to precision medicine, research and development, and the introduction of novel therapies and diagnostics underscores a collective effort to improve treatment efficacy and patient outcomes. As the ACS market continues to evolve towards a patient-centered, stratified care model, the contributions of these companies remain essential in shaping the future of cardiovascular medicine and enhancing the quality of care for individuals affected by ACS.
